Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes

The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.

Study Overview

• Status: Completed
• Conditions: Myelodysplastic Syndromes
• Intervention / Treatment: Drug: azacitidine

Detailed Description

Comparison/Control Interventions: The comparison is azacitidine at different doses and schedules.

Duration of Intervention: Treatment lasted for a maximum of 18 cycles, which is up to 24 months.

• Study Type: Interventional
• Enrollment (Actual): 151
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Bakersfield, California, United States, 93309
      • Comprehensive Blood and Cancer Center, Research Department
    • Beverly Hills, California, United States, 90211
      • Tower Cancer Research Foundation
  • Colorado
    • Colorado Springs, Colorado, United States, 80907
      • Cancer Center of Colorado Springs, The Oncology Clinic, PC
    • Denver, Colorado, United States, 80218
      • Rocky Mountain Cancer Centers, LLP
  • District of Columbia
    • Washington, District of Columbia, United States, 20010
      • Washington Cancer Institute
  • Florida
    • New Port Richey, Florida, United States, 34652
      • Florida Cancer Institute
    • Ocoee, Florida, United States, 34761
      • Cancer Centers of Florida, P.A.
  • Illinois
    • Joliet, Illinois, United States, 60435
      • Joliet Oncology-Hematology Associates, Ltd.
    • Peoria, Illinois, United States, 61615-7828
      • Oncology/Hematology Associates of Central Illinois, PC
  • Indiana
    • Indianapolis, Indiana, United States, 46227
      • Central Indiana Cancer Centers
  • Louisiana
    • Metairie, Louisiana, United States, 70115
      • Hematology & Oncology Specialists LLC
  • Michigan
    • Lansing, Michigan, United States, 48910
      • Great Lakes Cancer Institute Breslin Cancer Center
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • The Center for Cancer Care and Research
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack University Medical Center
  • Ohio
    • Kettering, Ohio, United States, 45409
      • Greater Dayton Cancer Center
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15224
      • Western Pennsylvania Cancer Institute
  • South Dakota
    • Aberdeen, South Dakota, United States, 57401
      • Oncology Services of Aberdeen
    • Sioux Falls, South Dakota, United States, 57105
      • Avera Cancer Institute Leukemia-Bone Marrow Transplant Center
  • Tennessee
    • Johnson City, Tennessee, United States, 37604
      • McLeod Cancer and Blood Center
    • Nashville, Tennessee, United States, 37203
      • The Sarah Cannon Research Institute
  • Texas
    • Bedford, Texas, United States, 76022
      • Texas Oncology, P.A.
    • Dallas, Texas, United States, 75230
      • Texas Cancer Center at Medical City
    • Fort Worth, Texas, United States, 76104
      • Texas Oncology, PA
    • Fredericksburg, Texas, United States, 78624
      • San Antonio Tumor & Blood Clinic
    • San Antonio, Texas, United States, 78229
      • Cancer Care Centers of South Texas - HOAST
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Virginia Oncology Associates - Lake Wright Cancer Center
  • Washington
    • Burien, Washington, United States, 98166
      • Highline Medical Oncology
    • Edmonds, Washington, United States, 98026
      • Puget Sound Cancer Center
    • Seattle, Washington, United States, 98133
      • Puget Sound Cancer Center
    • Spokane, Washington, United States, 99218
      • Cancer Care Northwest
    • Vancouver, Washington, United States, 98684
      • Northwest Cancer Specialists, P.C.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of refractory anemia, refractory anemia with ringed sideroblasts and at least one of the following: a)Anemia with hemoglobin <110g/L and requires at least 1 unit packed red blood cell transfusions every 28 days; b)Thrombocytopenia with platelet counts <100 x 10^9/L; or c)Neutropenia with absolute neutrophil count <1.5 x 10^9/L.
• OR, Refractory anemia with excess blasts or refractory anemia with excess blast in transformation, according to the French-American-British classification system for MDS.
• At least 18 years of age.
• Have a life expectancy of >7 months.
• Unlikely to proceed to bone marrow or stem cell transplantation therapy following remission.
• Have serum bilirubin levels less than or equal to 1.5 times the upper limit of the normal (ULN) range for the laboratory.
• Have serum glutamic-oxaloacetic transaminase (aspartate aminotransferase) or serum glutamic-pyruvic transaminase (alanine aminotransferase) levels less than or equal to 2 x ULN.
• Have serum creatinine levels less than or equal to 1.5 x ULN.

Exclusion Criteria:

• Secondary MDS.
• Prior treatment with azacitidine.
• Any prior history of Acute Myeloid Leukemia (AML).
• Malignant or metastatic disease within the previous 12 months.
• Uncorrected red cell folate deficiency or vitamin B12 deficiency.
• Hepatic tumors.
• Radiation, chemotherapy, or cytotoxic therapy for non-MDS conditions in the previous 12 months.
• Known or suspected hypersensitivity to azacitidine or mannitol.
• Prior transplantation or cytotoxic therapy to treat MDS. Prior use of Revlimid and Thalomid allowed after 30 day washout.
• Serious medical illness likely to limit survival to less than or equal to 7 months.
• Treatment with androgenic hormones during the previous 14 days
• Active viral infection with known human immunodeficiency virus or vial hepatitis Type B or C.
• Treatment with other investigational drugs with the previous 30 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Aza-5; Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.	Drug: azacitidine; Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.
Experimental: Aza-5-2-2; Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.	Drug: azacitidine; Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.
Experimental: Aza-5-2-5; Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.	Drug: azacitidine; Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.
Experimental: Maintenance Aza 5 days q 4 weeks; Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.	Drug: azacitidine; Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.
Experimental: Maintenance Aza 5 days q 6 weeks; Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.	Drug: azacitidine; Azacitidine is administered subcutaneously Total of 18 cycles on treatment or early discontinuation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants In Best Hematological Response Categories as Determined by the Investigator Using International Working Group 2000 (IWG 2000) Criteria For Myelodysplastic Syndromes (MDS) During the Initial Study Period.	Participant counts by best hematological response; complete remission(CR) is better than a partial remission(PR) which is better than stable disease(SD). Investigator determined responses followed IWG 2000 criteria for MDS CR: repeat bone marrow show <5% myeloblasts, and peripheral blood evaluations lasting >=2 months of hemoglobin(>110 g/L), neutrophils(>=1.5x10^9/L), platelets(>=100x10^9/L), blasts (0%) and no dysplasia PR is the same as CR for peripheral blood: bone marrow shows blasts decrease by >=50% or a less advanced FAB classification from pretreatment (see Population Descrip)	Day 1 (randomization) to 6 months
Number of Participants With Best Hematological Improvement Derived Using International Working Group 2000 (IWG 2000) Criteria for MDS During the Initial Study Period.	IWG 2000 Criteria: Pretreatment=hemoglobin <110g/L or RBC transfusion-dependence, platelet count <100x10^9/L or platelet transfusion dependence, absolute neutrophil count <1.5x10^9/L. Erythroid response: Major->20g/L increase in hemoglobin or transfusion independence. Minor- 10-20g/L increase in hemoglobin or >=50% decrease in transfusion requirements. Platelet response: Major-absolute increase of platelet count by >=30x10^9/L or platelet transfusion independence. Minor->=50% increase in platelet count with net increase >10x10^9/L but <30x10^9/L. (continued in Population Description)	Day 1 (randomization) to 6 months
Number of Participants With Overall Best Hematologic Response and Hematologic Improvement Based on IWG 2000 Criteria For MDS During the Initial Study Period	Number of participants whose best hematological outcome was either complete remission (CR), partial remission (PR) (as determined by the investigator), or any hematologic improvement (based on the IWG 2000 criteria for MDS). See previous outcomes for detailed definitions.	Day 1 (randomization) to 6 months
Number of Participants Who Improved or Maintained The Hematologic Response From the Initial Study Period (Based on IWG 2000 Criteria For MDS) During the Maintenance Period	Hematologic response during the maintenance period are compared to the response in the initial study period. Initial response could have been a complete remission, a partial remission, stable disease or a hematologic improvement. Maintenance period best response is after randomization to a maintenance arm for those randomized, and is after the start of cycle 7 for those remaining on initial period treatment throughout the study.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Baseline Hemoglobin Values	The median values for hemoglobin based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for hemoglobin. Baseline values are used to compare to values following treatment.	Day 1 (randomization)
Change From Baseline in Hemoglobin at End of Initial Study Period (6 Months)	The difference between hemoglobin values at the end of the initial study period minus the hemoglobin values at baseline.	6 months
Change From Baseline in Hemoglobin at the End of the Maintenance Study Period	The difference between hemoglobin values at the end of the maintenance study period minus the hemoglobin values at baseline.	24 months
Baseline Platelet Values	The median values for platelets based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for platelets. Baseline values are used to compare to values following treatment.	Day 1 (randomization)
Change From Baseline in Platelets at the End of Initial Study Period (6 Months)	The difference between platelet values at the end of the initial study period minus the platelet values at baseline.	6 months
Change From Baseline in Platelets at the End of the Maintenance Study Period (Month 24)	The difference between platelet values at the end of the maintenance study period minus the platelet values at baseline.	24 months
Baseline Absolute Neutrophil Count (ANC) Values	The median values for ANC based on blood tests performed on study day 1 (prior to study treatment) constitute a baseline measure for ANC. Baseline values are used to compare to values following treatment.	Day 1 (randomization)
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of Initial Study Period (6 Months)	The difference between ANC values at the end of the initial study period minus the ANC values at baseline.	6 months
Change From Baseline in Absolute Neutrophil Count (ANC) at the End of the Maintenance Study Period (Month 24)	The difference between ANC values at the end of the maintenance study period minus the ANC values at baseline.	24 months
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Initial Study Period (6 Months)	Shift table comparing the RBC transfusion status of patients at the end of the initial study period to the transfusion status at baseline.	6 months
Platelet Transfusion Status at Baseline and End of Initial Study Period (6 Months)	Shift table comparing the platelet transfusion status of patients at the end of the initial study period to the transfusion status at baseline.	6 months
Red Blood Cell (RBC) Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)	Shift table comparing the RBC transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.	24 months
Platelet Transfusion Status at Baseline and End of Maintenance Study Period (24 Months)	Shift table comparing the platelet transfusion status of patients at the end of the maintenance study period to the transfusion status at baseline.	24 months
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Initial Study Period	Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Initial study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).	6 months
Change From Baseline in the Number of Infections Requiring Treatment With IV Antibiotics Per Treatment Cycle (28 Days) for the Maintenance Study Period	Baseline uses the average number of infections requiring IV antibiotic treatment from the 28 days prior to and including the day of first dose to an initial treatment arm. Maintenance study period values total the number of infections requiring IV antibiotic treatment divided by the number of treatment cycles (each cycle is approximately one month).	24 months

Collaborators and Investigators

• Sponsor: Celgene
• Investigators: Study Director: CL Beach, Celgene Corporation

Publications and helpful links

General Publications

• R. Lyons, et al. Rapid onset of effectiveness with three alternative azacitidine (aza) dosing regimens in patients (pts) with myelodysplastic syndromes (MDS). Haematologica 2008;93(suppl 1):Abs.0232.
• Lyons R, et al. Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Presented at the 2007 ASCO Annual Meeting, June 1-5, 2007, Chicago, IL. Abstract No. 7083
• Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 Feb;23(2):159-170. doi: 10.1634/theoncologist.2017-0215. Epub 2017 Nov 8.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2005
• Primary Completion (Actual): August 1, 2008
• Study Completion (Actual): August 1, 2008

Study Registration Dates

• First Submitted: January 31, 2005
• First Submitted That Met QC Criteria: January 31, 2005
• First Posted (Estimate): February 1, 2005

Study Record Updates

• Last Update Posted (Actual): November 22, 2019
• Last Update Submitted That Met QC Criteria: November 7, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Preleukemia; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Azacitidine
• Other Study ID Numbers: AZA PH US 2004 CL003